Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
TORU TAKIMOTO · UNIVERSITY OF ROCHESTER · 2021 · $385,000 — Virus infection induces a wide range of host defense mechanisms, such as the innate immune response and inflammation. Some viruses express accessory proteins to induce general shutoff of host protein synthesis, which is considered to be one of the major viral strategies to counteract host antiviral …
Yogesh K Gupta · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2021 · $608,161 — ABSTRACT The massive global pandemic with high morbidity and mortality makes Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) one of the deadliest viruses in recent history. It is especially noteworthy for hijacking the normal operations of human cells. To develop effective therapies, we…
Alexander Arthur Green · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · 2021 · $1,173,739 — Project Summary Fast, inexpensive, and sensitive methods to detect the SARS-CoV-2 coronavirus are instrumental in containing the spread of COVID-19. Currently, nucleic acid testing of respiratory samples using RT-PCR is the primary and most commonly used method for diagnosing patients in the acute p…
Bethany K Crouse · UNIVERSITY OF MINNESOTA · 2021 · $26,961 — Project Summary. In the United States, there are over 2.5 million people diagnosed with opioid use disorder (OUD) and over 47,000 opioid-related fatal overdoses occur annually. Current FDA-approved medications against OUD and overdose consist of opioid receptor agonists and antagonists, which overal…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2021 · $783,564 — Abstract A vaccine for prevention of genital herpes is a high public health priority. Herpes vaccines that performed well in rodents have not protected humans; therefore, novel approaches are needed. We propose the following: 1) Set a much higher bar for vaccine efficacy in animal models than used p…
Hui Hu · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2021 · $491,617 — Project Summary CD4+ T follicular helper (Tfh) cells are essential for germinal center (GC) responses and long- term humoral immunity. However, the complex regulation that determines the differentiation of Tfh cells, their developmental progression in GC, and their number and function in helping GC…
MARK J SHLOMCHIK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $566,202 — Immune memory is critical for pathogen resistance as well as for vaccine efficacy; it is a defining feature of adaptive immunity. To deepen our fundamental understanding of how immune memory works we have fo- cused on elucidating the inherent differences between memory B cells (MBC) and naïve B cell…
YURIJ IONOV · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · 2021 · $466,702 — PROJECT SUMMARY/ABSTRACT We propose to create a library of chemotherapy-induced cancer neoepitopes (chemo-neoepitopes) that are shared between breast cancers, do not have to be customized for each tumor, and can be used for immunotherapy of any cancers with mutated p53. This approach is based on the…
Ranjit Ray · SAINT LOUIS UNIVERSITY · 2021 · $340,875 — Abstract Chronic hepatitis C virus (HCV) infection often causes end stage liver disease. Although current anti-HCV drugs are successful in eliminating viral RNA load, they do not prevent reinfection. In addition, eliminating HCV RNA load does not reduce the risk for progression to end stage liver di…
Jordan Fong · GRADIENT MEDICAL, INC. · 2021 · $251,914 — Project Summary / Abstract This applications long-term objective is to develop a platform technology enabling in vivo genetic engineering technologies including DNA vaccination and precision CRISPR gene editing. A challenge in utilizing CRISPR technologies in vivo is the need to simultaneously deliv…
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $299,339 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…
Clarence Buddy Creech · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $5,245,366 — Program Director/Principal Investigator (Last, First, Middle): Creech, Clarence B Supplement Abstract Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effec…
Laura Su · UNIVERSITY OF PENNSYLVANIA · 2021 · $658,748 — Project Summary An ongoing outbreak of a novel coronavirus infection (COVID-19) has claimed millions of lives and disrupted social infrastructures around the world. Fortunately, the new mRNA vaccines from Moderna or Pfizer/BioNTech are highly effective against SARS-CoV-2. However, much remains unkno…
SIMON R BEST · JOHNS HOPKINS UNIVERSITY · 2021 · $22,318 — Dr. Simon Best is a junior faculty member in the Department of Otolaryngology – Head and Neck Surgery at the Johns Hopkins School of Medicine where his clinical practice is dedicated to voice and airway disorders. With the support of this Mentored Career Development Award, Dr. Best seeks to better u…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2021 · $391,800 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…
Leor S Weinberger · J. DAVID GLADSTONE INSTITUTES · 2021 · $189,000 — ABSTRACT Substantial evidence now indicates that HIV-infected individuals are at a significantly elevated risk for severe COVID-19 disease when infected with SARS-CoV-2. Moreover, persons who use and inject drugs (PWUD and PWID) have a high-risk of HIV infection and exposure to SARS-CoV-2 and face m…
EVAN J ANDERSON · EMORY UNIVERSITY · 2021 · $1,475,091 — Narrative The Emory VTEU will participate and enroll children into “A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2…
MYRON Scott COHEN · FAMILY HEALTH INTERNATIONAL · 2021 · $21,074,900 — PROJECT SUMMARY The overarching goal of the HIV Prevention Trials Network (HPTN) is to identify acceptable, feasible, safe, effective and scalable interventions for HIV prevention that address the needs of populations at risk in the U.S. and around the world. The HPTN will address this goal by ident…
James A Hoxie · UNIVERSITY OF PENNSYLVANIA · 2021 · $761,861 — Project Summary In pathogenic HIV and SIV infection innate and adaptive immune responses fail to control viral replication and, coupled with persisting immune activation, lead to the progressive depletion of CD4+/CCR5+ T cells and AIDS. Numerous HIV and SIV vaccines have also failed to elicit immune…
Brian Geiss · COLORADO STATE UNIVERSITY · 2021 · $374,993 — Approximately 2/3rd of the world population is at risk of infection by at least one of the 35 insect-borne flaviviruses known to cause disease in humans. There are currently few vaccines and no therapeutics available to treat patients infected by flaviviruses such as Dengue, Zika, and West Nile viru…